Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 328: FluMos-v2 With and Without ALFQ Adjuvant in Healthy Adults
NCT06863142Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FluMos-v2 in influenza (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and tolerability of the FluMos-v2 vaccine at 68 weeks. Started Apr 2025; status: recruiting.
02
Drugs
FluMos-v2
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06863142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863142.